Propanc Biopharma, Inc.
PPCB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $30 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $5 | $4 |
| Gross Profit | $0 | $15 | -$5 | -$4 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $60 | $54 | $54 | $54 |
| G&A Expenses | $0 | $3,592 | $53,075 | $159 |
| SG&A Expenses | $0 | $3,592 | $53,075 | $159 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4,613 | $0 | -$0 | -$0 |
| Operating Expenses | $4,674 | $3,645 | $53,129 | $209 |
| Operating Income | -$4,674 | -$3,645 | -$53,129 | -$213 |
| % Margin | – | -12,189.8% | – | – |
| Other Income/Exp. Net | -$164 | -$426 | -$939 | -$217 |
| Pre-Tax Income | -$4,838 | -$4,071 | -$54,067 | -$430 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,838 | -$4,071 | -$54,067 | -$430 |
| % Margin | – | -13,615.1% | – | – |
| EPS | -0.39 | -0.35 | -12.5 | -32.22 |
| % Growth | -11.4% | 97.2% | 61.2% | – |
| EPS Diluted | -0.39 | -0.35 | -12.5 | -32.22 |
| Weighted Avg Shares Out | 12,332 | 11,611 | 4,326 | 13 |
| Weighted Avg Shares Out Dil | 12,332 | 11,612 | 4,326 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $306 | $255 | $104 | $119 |
| Depreciation & Amortization | $3,028 | $5 | $5 | $4 |
| EBITDA | -$1,504 | -$3,812 | -$53,958 | -$307 |
| % Margin | – | -12,746.4% | – | – |